Fresenius Kabi USA Inc. v. Coherus BioSciences, Inc. (PGR2019-00064)
Mar 19, 2020OUTCOME: Petition Dismissed and rehearing denied
Defended client's adalimumab formulation patent number U.S. 10,155,039 covering a biosimilar of the top-selling drug in the world, Humira®. In its Final Written Decision, the Board agreed with our argu ... ments and denied all of the challenges to our client's patent.
